Abnormal glucose tolerance in Egyptian beta-thalassemic patients: Possible association with genotyping

Pediatric Diabetes

Volumn 5, Issue 3, 2004, Pages 126-132

  Khalifa, A Samy ^a   Salem, Mona ^a   Mounir, Eman ^a   El Tawil, M M ^a   El Sawy, Mohamed ^a   Abd Al Aziz, Manal M ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Abnormal glucose tolerance; Genotyping; Thalassemia

Indexed keywords

C PEPTIDE; DEFEROXAMINE; FERRITIN; GLUCOSE; INSULIN;

ADOLESCENT; ADULT; ANAMNESIS; ARTICLE; BETA THALASSEMIA; BLOOD CELL COUNT; BLOOD TRANSFUSION; CELL LOSS; CLINICAL EXAMINATION; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; EGYPT; ETHNOLOGY; FEMALE; FERRITIN BLOOD LEVEL; GENE MUTATION; GENOTYPE; GLUCOSE BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LABORATORY TEST; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET CELL; PATHOGENESIS; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; C-PEPTIDE; CHILD; DIABETES MELLITUS; EGYPT; FEMALE; GENOTYPE; GLUCOSE INTOLERANCE; HEPATITIS C, CHRONIC; HUMANS; MALE;

EID: 6444227288     PISSN: 1399543X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-543X.2004.00051.x     Document Type: Article

References (37)

1. Khalifa AS, Baffico M, Heshmat NM, Gadallah MA, Romeo G, Rady MS. Relationship between the hematological phenotype and the type of β-thalassemia mutation in Egyptian children. Egypt J Hematol 1995: 20: 130-139.
2. Rady MS, Baffico M, Khalifa AS et al. Identification of Mediterranean β-thalassemia mutations by reverse dot-blot in Italians and Egyptians. Hemoglobin 1997: 21: 59-69.
3. Zurlo MG, De Stefano P, Borgna-Pignatti C et al. Survival and causes of death in thalassemia major. Lancet 1989: 2: 27-30.
4. Saudek CD, Hemm RM, Peterson CM. Abnormal glucose tolerance in β-thalassemia major. Metabolism 1977: 16: 43-52.
5. Gabutti V, Piga A. Results of long-term iron chelation therapy. Acta Haematol 1996: 95: 26-36.
6. Borgna-Pignatti C, Rugolloto S, De Stefano P et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998: 850: 227-231.
7. De Sanctis V, Zurlo MG, Senesi E et al. Insulin dependent diabetes in thalassemia. Arch Dis Child 1988: 63: 58-62.
8. Italian Working Group on Endocrine Complications in Non-endocrine Diseases. Multicenter study on prevalence of endocrine complications in thalassemia major. Clin Endocrinol 1995: 42: 581-586.
9. Arigo T, Crisafulli G, Meo A et al. Glucose tolerance, insulin secretion and peripheral sensitivity in thalassemia major. J Pediatr Endocrinol Metab 1998: 11 (Suppl. 3): 863-866.
10. Gamberini MR, Fortini M, Gilli G, Terta MR, De Sanctis V. Epidemiology and chelation therapy effects on glucose homeostasis in thalassemia patients. J Pediatr Endocrinol Metab 1998: 11 (Suppl. 3): 867-869.
11. Cher JPS, Lin KH, Lu MY, Lin KS, Chen JD, Fu CC. Abnormal glucose tolerance in transfusion dependant beta thalassemia. Diabetes Care 2001: 24: 850-854.
12. El-Nawawy A, Soliman AT, El-Azzouni O et al. Interleukin 1-beta, tumour necrosis factor-alpha, islet-cell antibody and insulin secretion in children with thalassemia major on long-term blood transfusion. J Trop Pediatr 1996: 42: 362-364.
13. Monge L, Pinach S, Caramellino L, Bertero MT, Dall'omo A, Carta Q. The possible role of autoimmunity in the pathogenesis of diabetes in β-thalassemia major. Diabetes Metab 2001: 27 (2 Part 1): 149-154.
14. Merkel PA, Simonson DC, Amiel SA et al. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N Engl J Med 1988: 318: 809-814.
15. Ladis V, Theodorides C, Palamidou F, Frissiras S, Berdousi H, Kattamis C. Glucose disturbances of regulation with glibenclamide in thalassemia. J Pediatr Endocrinol Metab 1998: 11 (Suppl. 3): 871-878.
16. Jansen CE, Tuck SM, Old J et al. Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with beta-thalassemia. Eur J Haematol 1997: 59: 76-81.
17. De Sanctis V, D'Ascola G, Wonke B. The development of diabetes mellitus and chronic liver disease in long-term chelated beta thalassemic patients. Postgrad Med J 1986: 62: 831-836.
18. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1999: 22 (Suppl. 1): 5-9.
19. Sacks DB. Carbohydrates. In: Burtis CA, Ashwood ER, eds. Teitz Textbook of Clinical Chemistry, 3rd edn. Vol. 2. Philadelphia, PA: W.B. Saunders Com, 1999: 770.
20. Bonser A, Garcia-Webb P. C-peptide measurement: methods and clinical utility. Crit Rev Clin Lab Sci 1984: 19: 297-352.
21. Newton CR, Graham A, Hepatinstall LE. Analysis of any point mutation in DNA: the amplification refractory mutation system (ARMS). Nucleic Acids Res 1989: 17: 2503-2516.
22. Sutcharitchan P, Saiki R, Fucharoen S, Winichagoon P. Reverse dot-blot detection of Thai beta thalassemia mutations. Br J Haematol 1995: 90: 809-816.
23. Colosimo A, Novelli G, Cavicchini A, Dallapiccola A. Detection of eight β-thalassemia mutations using a DNA enzyme immunoassay. Int J Clin Lab Res 1996: 26: 136-139.
24. Maggio A, Giambona SP, Wall J, Kan YW, Chehab FF. Rapid and simultaneous typing of hemoglobin S, hemoglobin C and seven Mediterranean B thalassemia mutations by covalent reverse Dot-blot analysis: application to prenatal diagnosis in Sicily. Blood 1993: 81: 239-242.
25. Ramachandran A, Snehalatha C, Kapur A et al. High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia 2001: 44: 1094-1101.
26. El-Hazmi MA, al-Swailem A, al-Fawaz I, Warsey AS, Al-Swailem A. Diabetes mellitus in children suffering from beta-thalassemia. J Trop Pediatr 1994: 40: 261-267.
27. Zuppinger K, Molinari B, Hirt A. Increased risk of diabetes mellitus in beta-thalassemia major due to iron overload. Helv Paediatr Acta 1979: 34: 197-207.
28. Cario H, Holl RW, Debatin KM, Kohne E. Disproportionately elevated fasting proinsulin levels in normoglycemic patients with thalassemia major are correlated to the degree of iron overload. Horm Res 2003: 59: 73-78.
29. Dmochowski K, Finegood DT, Francombe W, Tyler B, Zinman B. Factors determining glucose tolerance in patients with thalassemia major. J Clin Endocrinol Metab 1993: 77: 478-483.
30. Cario H, Holl RW, Debatin KM, Kohne E. Insulin sensitivity and beta-cell secretion in thalassemia major with secondary haemochromatosis: assessment by oral glucose tolerance test. Eur J Pediatr 2003: 162: 139-146.
31. Fernandez-Real JM, Ricart-Engel W, Arroyo E et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998: 21: 62-68.
32. Kowdley KV, Kaplan MM. Iron chelation therapy with oral deferiprone: toxicity or lack of efficacy? N Engl J Med 1998: 339: 468-469.
33. Labropoulou-Karataza C, Gortisas C, Fragopanagou H, Repandi M, Matsouka P, Alexandrides T. High prevalence of diabetes mellitus among adult β-thalassemic patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1999: 11: 1033-1036.
34. Hussein I, Temtamy S, El-Beshlawy A et al. Molecular characterization of β thalassemia in Egyptians. Hum Mutat 1993: 2: 48-52.
35. Hazmi MA, Warsy AS, Swailem AR. The frequency of 14 beta thalassemia mutations in the Arab populations. Hemoglobin 1995: 19: 353-360.
36. Zahed L. The spectrum of -thalassemia mutations in the Arab populations. J Biomed Biotechnol 2001: 1: 129-132.
37. Verma RS, Babu A, eds. Human Chromosomes: Principles and Techniques, 2nd edn. New York: McGraw-Hill Inc, 1995.